Perrigo CEO: Think Mylan’s buyout will come easily? Think again

Carly Helfand

has stayed quiet since Teva dropped its hostile pursuit of Mylan, choosing instead to snap up Allergan's generics business for $ 40.5 billion. Mylan's shares plummeted on that news. And now, has broken its silence–and the word isn't what Mylan wants to hear.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS